natgillin/translations-raw huggingface dataset:
filtering at least a part of the resulting suspension S by passing at least a part of the resulting suspension S through a filtering device in order to obtain the aqueous solution comprising at least one earth alkali hydrogen carbonate, wherein the aqueous solution obtained after filtration has a turbidity value of lower than 1 NTU and has a calcium concentration, as calcium carbonate, from 50 to 650 mg/l, 
filtriranje barem dijela dobivene suspenzije S prolaskom barem dijela dobivene suspenzije S kroz uređaj za filtriranje kako bi se dobila vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat, pri čemu vodena otopina koja je dobivena nakon filtriranja ima vrijednost zamućenja manju od 1 NTU i ima koncentraciju kalcija, kao kalcijevog karbonata, od 50 do 650 mg/l,
Process according to any one of claims 1 to 5, characterized in that the resulting suspension S that is obtained in step d) has a solids content in the range of 3 to 35 wt.%, more preferably in the range of 5 to 35 wt.%, based on the total weight of the resulting suspension S. 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time da dobivena suspenzija S koja je dobivena u koraku d) ima udio krutih tvari u rasponu od 3 do 35 tež.%, poželjnije u rasponu od 5 do 35 tež.%, bazirano na ukupnoj težini dobivene suspenzije S.
Process according to any one of claims 1 to 9, characterized in that the amount of CO2 used, in mol, to produce 1 mol of the at least one earth alkali hydrogen carbonate in the aqueous solution is in the range of 0.5 to 4 mol, preferably in the range of 0.5 to 2.5 mol, more preferably in the range of 0.5 to 1.0 mol, and most preferably in the range of 0.5 to 0.65 mol. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time da je količina korištenog CO2, u mol, da se proizvede 1 mol barem jednog zemnoalkalijskog hidrogenkarbonata u vodenoj otopini u rasponu od 0.5 do 4 mol, poželjno u rasponu od 0.5 do 2.5 mol, poželjnije u rasponu od 0.5 do 1.0 mol, i najpoželjnije u rasponu od 0.5 do 0.65 mol.
Process according to any one of claims 1 to 11, characterized in that the aqueous solution comprising at least one earth alkali hydrogen carbonate and that is obtained in step e) has a pH in the range of 6.5 to 9, preferably in the range of 6.7 to 7.9, and most preferably in the range of 6.9 to 7.7, at 20°C. 
Postupak prema bilo kojem od zahtjeva 1 do 11, naznačen time da vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat i koja se dobiva u koraku e) ima pH u rasponu od 6.5 do 9, poželjno u rasponu od 6.7 do 7.9, te najpoželjnije u rasponu od 6.9 do 7.7, kod 20°C.
Process according to any one of claims 1 to 13, characterized in that the aqueous solution comprising at least one earth alkali hydrogen carbonate that is obtained in step e) has a magnesium concentration, as magnesium carbonate, from 1 to 200 mg/l, preferably from 2 to 150 mg/l, and most preferably from 3 to 125 mg/l. 
Postupak prema bilo kojem od zahtjeva 1 do 13, naznačen time da vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat koja se dobiva u koraku e) ima koncentraciju magnezija, kao magnezijevog karbonata, od 1 do 200 mg/l, poželjno od 2 do 150 mg/l, te najpoželjnije od 3 do 125 mg/l.
Process according to any one of claims 1 to 14, characterized in that the aqueous solution comprising at least one earth alkali hydrogen carbonate that is obtained in step e) has a turbidity value of lower than 0.5 NTU, and preferably of lower than 0.3 NTU. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat koja se dobiva u koraku e) ima vrijednost zamućenja manju od 0.5 NTU, te poželjno manju od 0.3 NTU.
Use of an aqueous solution comprising at least one earth alkali hydrogen carbonate obtained by the process according to any one of claims 1 to 21 for the production of a precipitated earth alkali carbonate and/or hydromagnesite, and in particular for the production of a precipitated calcium carbonate and/or hydromagnesite. 
Uporaba vodene otopine koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat dobiven sa postupkom prema bilo kojem od zahtjeva 1 do 18 naznačena time da je za proizvodnju istaloženog zemnoalkalijskog karbonata i/ili hidromagnezita, te naročito za proizvodnju istaloženog kalcijevog karbonata i/ili hidromagnezita.
Process for the mineralization of water comprising the following steps: 
Postupak za mineraliziranje vode naznačen time da sadrži slijedeće korake:
Compound according to claim 2, wherein Y is -H or a linker 
Spoj prema zahtjevu 2, gdje Y je -H ili linker (poveznica).
Compound according to any of the preceding claims, wherein the compound is attached to another molecule via said linker. 
Spoj prema bilo kojem od prethodnih zahtjeva, gdje je spoj vezan za drugu molekulu preko linkera.
eliminating pthalamide group from compound of formula (VI), in suitable solvent using a suitable de-protecting agent to get compound formula (VII), as a free base, which further treated with acid to obtained acid addition salt of compound formula (VII); A is acid addition salt 
uklanjanja skupine ptalamida iz spoja formule (VI) u prikladnom otapalu korištenjem prikladnog sredstva za skidanje zaštite kako bi se dobio spoj formule (VII), kao slobodna baza, koja se dalje tretira s kiselinom kako bi se dobila kisela adicijska sol spoja formule (VII);
treating compound formula (A), with compound formula (VIII) or 5-chlorothiophene-2-carbonitrile in suitable solvents selected from mehtylene dichloride, acetone, toluene and ether or mixture thereof in presence of base to obtain the compound formula (B), Wherein; 
tretiranja spoja formule (A) sa spojem formule (VIII) ili 5-klorotiofen-2-karbonitrilom u prikladnim otapalima odabranim od metilen diklorida, acetona, toluena i ili njihov smjesa u nazočnosti baze kako bi se dobio spoj formule (B), [image] pri čemu;
the compound formula (B) obtained from step(c), is slurred with methanol and filter, the obtained solid washed by methanol and dried to get purified compound formula (B). 
spoj formule (B) dobiveno u koraku (c) se spaja s metanolom i filtrira, dobivena krutina se pere metanolom i suši kako bi se dobio pročišćeni spoj formule (B).
A process as claimed in claim 2 wherein, step (a) is carried out in suitable solvents independently selected from isopropyl alcohol and water or mixture thereof. 
Postupak iz patentnog zahtjeva 2, naznačen time, da se korak (a) izvodi u prikladnim otapalima koji su neovisno odabrani od izopropil alkohola i vode ili smjese istih.
A process as claimed in claim 2 wherein, cyclization in step (b) is carried out in methylene dichloride with potassium carbonate as a base. 
Postupak iz patentnog zahtjeva 2, naznačen time, da se cikliranje u koraku (b) izvodi u metilen dikloridu s kalijevim karbonatom kao bazom.
A process as claimed in claim 2 wherein, elimination of pthalamide group in step (c) is carried out in methanol with methylamine as a base to obtain a free base of compound formula(VII). 
Postupak iz patentnog zahtjeva 2, naznačen time, da se eliminacija skupine ptalamida u koraku (c) izvodi u metanolu s metilaminom kao bazom kako bi se dobila slobodna baza spoja formule (VII).
A process as claimed in claim 2 wherein, in step (d), treating free base of compound formula (VII) with formic acid in suitable solvent (s) selected from methylene dichloride, ethylene dichloride, ether and toluene or mixture thereof, but preferably toluene. 
Postupak iz patentnog zahtjeva 2, naznačen time, da se u koraku (d), treatira slobodna baza spoja formule (VII) s mravljom kiselinom u prikladnom otapalu (s) koji je odabran od metilen diklorida, etilen diklorida, etera i toluena ili smjesa istih, ali je poželjno s toluenom.
A process as claimed in claim 2 wherein, in step (e), acid addition salt of compound formula (VII) is treated with base to obtained free base of compound formula (VII), and further step is carried out as claimed in claim 6. 
Postupak iz patentnog zahtjeva 2, naznačen time, da se u koraku (c), kisela adicijska sol spoja formule (VII) tretira s bazom kako bi se dobila slobodna baza spoja formule (VII), a sljedeći korak se izvodi sukladno patentnom zahtjevu 6.
A process as claimed in claim 2 wherein, departing of aldehyde group in step (f), is carried out in acid selected from methane sulphonic acid, hydrochloric acid and sulphuric acid or mixture thereof. 
Postupak iz patentnog zahtjeva 2, naznačen time, da se napuštanje aldehidne skupine u koraku (f) izvodi u kiselini koja je odabrana od metan sulfonske kiseline, klorovodične kiseline i sumporne kiseline ili smjesi istih.
A process as claimed in claim 2 wherein, step (h), rivaroxaban is precipitated out by adding methanol as an anti-solvent. 
Postupak iz patentnog zahtjeva 2, naznačen time, da u korak (h), rivaroksaban se istaloži dodavanjem metanola kao protuotapala.
provided that the ring formed by B, D, E, and F together with the atoms to which they are attached contains at least five atoms and zero or one of B, D or E is NR1 or O; 
uz uvjet da prsten načinjen od B, D, E i F zajedno s atomima za koji su pričvršćeni sadrži najmanje pet atoma i nula ili jedan B, D ili E je NR1 ili O;
A compound according to claim 12, wherein R4 is hetAr4 or hetAr5. 
Tvar u skladu s patentnim zahtjevom 10, gdje je R4 hetAr4 ili hetAr5.
A compound according to claim 16, wherein R5 is (1-6C)alkyl. 
Tvar u skladu s patentnim zahtjevom 12, gdje je R5 (1-6C)alkil.
A compound according to claim 29, wherein R5 is (1-6C)alkyl. 
Tvar u skladu s patentnim zahtjevom 17, gdje R5 predstavlja (1-6C)alkil.
A pharmaceutical composition, which comprises a compound of Formula I as defined in any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav, koji sadrži tvar formule I kako je definirana u bilo kojem od patentnih zahtjeva 1 do 23 ili njena farmaceutski prihvatljiva sol i farmaceutski prihvatljivi diluent ili nosač.
A compound of Formula I as defined in any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 24, for use in therapy. 
Tvar formule I kako je definirana u bilo kojem od patentnih zahtjeva 1 do 23, ili njena farmaceutski prihvatljiva sol, ili farmaceutski sastav u skladu s patentnim zahtjevom 24, za uporabu u liječenju.
A compound of Formula I as defined in any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 24, for use in the treatment of pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome. 
Tvar formule I kako je definirana u bilo kojem od patentnih zahtjeva 1 do 23, ili njena farmaceutski prihvatljiva sol, ili farmaceutski sastav u skladu s patentnim zahtjevom 24, za uporabu u liječenju boli, raka, upale/upalnih bolesti, neurodegenerativnih bolesti, određenih infektivnih bolesti, Sjogrenovog sindroma, endometrioze, dijabetičke periferne neuropatije, prostatitisa i sindroma pelvične boli.
The compound or pharmaceutical composition of claim 26, for use in the treatment of pain. 
Tvar ili farmaceutski sastav iz patentnog zahtjeva 26, za uporabu u liječenju boli.
The compound or pharmaceutical composition for use as defined in claim 27, wherein the pain is chronic pain. 
Tvar ili farmaceutski sastav za uporabu definiranu u patentnom zahtjevu 27, pri čemu je bol kronična bol.
The compound or pharmaceutical composition for use as defined in claim 27, wherein the pain is acute pain. 
Tvar ili farmaceutski sastav za uporabu definiranu u patentnom zahtjevu 27, pri čemu je bol akutna bol.
The compound or pharmaceutical composition for use as defined in claim 26, wherein said cancer is a cancer having a dysregulation of TrkA. 
Tvar ili farmaceutski sastav za uporabu definiranu u patentnom zahtjevu 26, pri čemu je navedeni rak rak koji ima disregulaciju TrkA.
for a compound of Formula I where X is O, coupling a corresponding compound having the formula II with a corresponding compound having the formula III in the presence carbonyldiimidazole or triphosgene and a base; or 
za tvar formule I gdje X predstavlja O, vezanje odgovarajuće tvari koja ima formulu II [image] s odgovarajućom tvari koja ima formulu III [image] u prisutnosti karbonildiimidazola ili trifosgena i baze; ili
for a compound of Formula I where X is S, coupling a corresponding compound having the formula II with a corresponding compound having the formula III in the presence di(1H-imidazol-2-yl)methanethione and a base; or 
za tvar formule I gdje X predstavlja S, vezanje odgovarajuće tvari koja ima formulu II [image] s odgovarajućom tvari koja ima formulu III [image] u prisutnosti di(1H-imidazol-2-il)metanetiona i baze; ili
for a compound of Formula I where X is O, coupling a corresponding compound having the formula II with a corresponding compound having the formula IV where L1 is a leaving group, in the presence of a base; or 
za tvar formule I gdje X predstavlja O, vezanje odgovarajuće tvari koja ima formulu II [image] s odgovarajućom tvari koja ima formulu IV [image] gdje je L1 grupa koja se otpušta, u prisutnosti baze; ili
for a compound of Formula I where X is O, coupling a corresponding compound having the formula V where L2 is a leaving group, with a corresponding compound having the formula III in the presence of a base; or 
za tvar formule I gdje X predstavlja O, vezanje odgovarajuće tvari koja ima formulu V [image] gdje je L2 grupa koja se otpušta, s odgovarajućom tvari koja ima formulu III [image] u prisutnosti baze; ili
for a compound of Formula I where X is O, coupling a corresponding compound having the formula II with a corresponding compound having the formula VII in the presence of a base; or 
za tvar formule I gdje X predstavlja O, vezanje odgovarajuće tvari koja ima formulu II [image] s odgovarajućom tvari koja ima formulu VII [image] u prisutnosti baze; ili
for a compound of Formula I where X is O, coupling a corresponding compound having the formula VIII with a corresponding compound having the formula III in the presence of a base; and optionally removing protecting groups and optionally preparing a pharmaceutically acceptable salt thereof 
za tvar formule I gdje X predstavlja O, vezanje odgovarajuće tvari koja ima formulu VIII [image] s odgovarajućom tvari koja ima formulu III [image] u prisutnosti baze; i opcionalno uklanjanje zaštitnih grupa i opcionalna priprava njene farmaceutski prihvatljive soli.
Device (12) according to any one of the preceding claims, characterized in that the closure element (16) has a body with a cylindrical shape. 
Uređaj (12) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što element za zatvaranje (16) ima tijelo u obliku valjka.
Device (12) according to any one of the preceding claims, characterized in that a cone-shaped surface is provided on the closing surface (18) of the closure element (16). 
Uređaj (12) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što površina za zatvaranje (18) elementa za zatvaranje (16) ima površinu u obliku stošca.
Device (12) according to any one of the preceding claims, characterized in that the material from which the closure element is made is alimentary silicone. 
Uređaj (12) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time stoje materijal od kojeg je načinjen element za zatvaranje prehrambeni silikon.
A pharmaceutical composition suitable for sublingual delivery, as well as rapid release of alfentanil therefrom and/or rapid uptake of alfentanil through the oral mucosa, which comprises a mixture comprising: 
Farmaceutski pripravak pogodan za sublingvalnu isporuku, kao i za brzo oslobađanje alfentanila iz njega i/ili brzo uzimanje alfentanila kroz sluznicu usta, koji sadrži smjesu naznačenu time da sadrži:
A composition for use as claimed in Claim 14 wherein the composition is administered not more than about 20 minutes prior to said procedure. 
Pripravak za uporabu kao što je definirano u zahtjevu 15 naznačen time da se pripravak primjenjuje ne više od oko 20 minuta prije postupka.
filtering at least a part of the resulting suspension S by passing at least a part of the resulting suspension S through a filtering device in order to obtain an aqueous solution comprising at least one earth alkali hydrogen carbonate, wherein the aqueous solution obtained after filtration has a turbidity value of lower than 1 NTU and a calcium concentration, as calcium carbonate, from 50 to 650 mg/l, 
filtriranje barem dijela dobivene suspenzije S prolaskom barem dijela dobivene suspenzije S kroz uređaj za filtriranje kako bi se dobila vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat, pri čemu vodena otopina koja je dobivena nakon filtriranja ima vrijednost zamućenja manju od 1 NTU i ima koncentraciju kalcija, kao kalcijevog karbonata, od 50 do 650 mg/l,
The process according to claim 1, wherein the aqueous solution comprising at least one earth alkali hydrogen carbonate obtained in step e) has a magnesium concentration, as magnesium carbonate, from 1 to 200 mg/l. The process according to claim 1, wherein the aqueous solution comprising at least one earth alkali hydrogen carbonate obtained in step e) has a magnesium concentration, as magnesium carbonate, from 2 to 150 mg/l. 
Postupak prema bilo kojem od zahtjeva 1 do 13, naznačen time da vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat koja se dobiva u koraku e) ima koncentraciju magnezija, kao magnezijevog karbonata, od 1 do 200 mg/l, poželjno od 2 do 150 mg/l, te najpoželjnije od 3 do 125 mg/l.
A process for the mineralization of water comprising the following steps: 
Postupak za mineraliziranje vode naznačen time da sadrži slijedeće korake:
a mode index configured to indicate one among candidate intra prediction modes included in a candidate list, wherein, the candidate list includes a fixed number of the candidate intra prediction modes comprising a planar mode, when the intra prediction modes of the left block and the upper block are equal to each other and the intra prediction mode of the left block is the DC mode. 
provođenje unutrašnjeg predviđanja trenutnog bloka uz korištenje načina predviđanja, koji je određen s indeksom načina, između kandidata načina unutrašnjeg predviđanja koji su uključeni u popis kandidata, naznačen time da popis kandidata načina unutrašnjeg predviđanja sadrži ravninski način, kada su načini unutrašnjeg predviđanja lijevog bloka i gornjega bloka međusobno jednaki i unutrašnji način lijevog bloka je DC način.
A comprises a first block segment selected from polypropylene oxide, polyethylene oxide, polytetramethyleneoxide, or mixtures thereof, and a second block segment comprising a polysiloxane or polydimethylsiloxane, wherein the A has a theoretical molecular weight of from 1,000 to 5,000 Daltons; 
A sadrži prvi blok segment odabran iz grupe koja se sastoji od polipropilen oksida, polietilen oksida, politetrametilenoksida i njihovih smjesa, i drugi blok segment koji se sastoji od polisiloksana ili polidimetilsiloksana, gdje A ima teorijsku molekulsku masu od 1000 do 5000 Daltona;
The compound according to claim 1, which is the hydrobromic acid salt of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine. 
Spoj za uporabu prema zahtjevu 1, koji je bromovodična sol 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
The compound according to claim 2, wherein said salt is crystalline. 
Spoj za uporabu prema zahtjevu 2, gdje je ta sol kristalična.
The compound according to claim 3, wherein said salt is characterised by having major XRDP peaks at 6.89, 9.73, 13.78 and 14.62 (°2θ), all ± 0.1 (°2θ). 
Spoj za uporabu prema zahtjevu 3, gdje je ta sol, naznačena time što ima glavne pikove rendgenske difrakcije praška (XRDP) na 6.89, 9.73, 13.78 i 14.62 (°2θ), svi ± 0.1 (°2θ).
The compound according to claim 4, wherein said salt is characterised by an XRDP as depicted in Figure 3. 
Spoj za uporabu prema zahtjevu 4, gdje je ta sol, naznačena XRDP-om kako je prikazan na Slici 3.
The compound according to any of claims 1-7 provided it is not the free base of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine in a non-crystalline form. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-7 uz uvjet da to nije slobodna baza 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina u ne-kristaličnom obliku.
The compound according to any of claims 1-8 for use in the treatment of a patient who has previously received medication (or is still receiving it) for the treatment of said disease which medication was ceased or reduced (or has to be ceased or reduced) due to sleep or sexually related adverse events. 
Spoj za uporabu prema bilo kojem od zahtjeva 1-8 za uporabu u liječenju bolesnika koji je prethodno dobivao lijek za liječenje navedene bolesti, a koji lijek je prekinut ili mu je smanjena doza zbog neželjenih dodagađaja vezanih uz san ili seksualnost.
A molecule comprising an antibody Fab fragment that specifically binds human Aβ peptide between amino acid positions 13 to 28, wherein the antibody fragment comprises a light chain variable region of SEQ ID NO: 1 and a heavy chain variable region of SEQ ID NO: 2, and wherein the said antibody Fab fragment is covalently attached to a 20 kD polyethylene glycol molecule at the cysteine at amino acid 56 of SEQ ID NO: 2. 
Molekula, naznačena time što sadrži fragment Fab protutijela koji se specifično veže na ljudski peptid Aβ, gdje fragment protutijela sadrži varijabilno područje lakog lanca sa SEQ ID NO: 1 i varijabilno područje teškog lanca sa SEQ ID NO: 2, gdje je navedeni fragment protutijela kovalentno vezan na molekulu polietilen-glikola na cisteinu na aminokiselinskom položaju 56 sa SEQ ID NO: 2, te gdje molekula polietilen-glikola ima molekulsku težinu od 0,5 kDa do 30 kDa.
The immunogenic composition of claim 5 wherein said one or more S.pneumoniae proteins are selected from Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins, detoxified pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133. The immunogenic composition according to any preceding claim which further comprises an adjuvant. 
Imunogeni pripravak u skladu s patentnim zahtjevom 5, naznačen time što se navedeni jedan ili više proteina iz bakterije S. pneumoniae biraju između obitelji polihistidinske trijade (PhtX), obitelj kolinski vežućih proteina (CbpX), skraćenih CbpX, obitelji LytX, skraćenih LytX, kimernih proteina skraćenog CbpX-skraćenog LytX, detoksiciranog pneumolizina (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 i Sp133.
Compound I, which is 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof for use in the treatment of a disease selected from mild cognitive impairment; vascular dementia; and cognitive impairment associated with Down's syndrome, tph gene mutations, epilepsy, traumatic brain injury or Asperger's syndrome. 
Spoj I, koji je 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazin i njegove farmaceutski prikladne soli za uporabu u liječenju bolesti odabrane između blagog kognitivnog poremećaja; vaskularne demencije, i kognitivnog poremećaja povezanog s Downovim sindromom, mutacijama tph gena, epilepsijom, traumatskom ozljedom mozga ili Aspergerovim sindromom.
The compound for use according to claim 1, which is the hydrobromic acid salt of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine. 
Spoj za uporabu prema zahtjevu 1, koji je bromovodična sol 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
The compound for use according to claim 2, wherein said salt is crystalline. 
Spoj za uporabu prema zahtjevu 2, gdje je ta sol kristalična.
The compound for use according to claim 3, wherein said salt is characterised by having major XRDP peaks at 6.89, 9.73, 13.78 and 14.62 (°2θ), all ± 0.1 (°2θ). 
Spoj za uporabu prema zahtjevu 3, gdje je ta sol, naznačena time što ima glavne pikove rendgenske difrakcije praška (XRDP) na 6.89, 9.73, 13.78 i 14.62 (°2θ), svi ± 0.1 (°2θ).